Literature DB >> 3025753

Active oxygen in methylguanidine synthesis.

S Nagase, K Aoyagi, M Narita, S Tojo.   

Abstract

Methylguanidine (MG), a toxin reported in uremia, is thought to be a product of creatinine oxidation. This study is designed to demonstrate the role of active oxygen in the oxidation of creatinine under conditions compatible with those found in uremia. MG synthesis is moderately stimulated by the superoxide radical derived from 3 mM hypoxanthine and 0.015 units/ml xanthine oxidase and inhibited by the addition of superoxide dismutase. This is increased markedly by the addition of 0.05% hydrogen peroxide and augmented to about 56,000 times the control rate in the presence of hydroxyl radicals derived from the reaction of 10 mM FeSO4 and 0.05% hydrogen peroxide. In addition, MG synthesis is inhibited by the addition of sorbitol, lactulose or ethanol, the scavengers of hydroxyl radicals. These results indicate that creatinine can be oxidized to MG by various species of active oxygen and that one of the mechanisms of MG synthesis is such oxidation. MG, therefore, may be a useful indicator of peroxidation in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025753     DOI: 10.1159/000184010

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Biochemical pathogenesis of post-traumatic epilepsy.

Authors:  A Mori; M Hiramatsu; I Yokoi; R Edamatsu
Journal:  Pavlov J Biol Sci       Date:  1990 Apr-Jun

2.  Effect of recombinant human erythropoietin on synthesis of methylguanidine in uraemic patients on haemodialysis or continuous ambulatory peritoneal dialysis.

Authors:  I Sasagawa; T Nakada; Y Kubota; T Sawamura; H Suzuki; T Hashimoto
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

3.  Uraemic toxins generated in the presence of fullerene C60, carbon-encapsulated magnetic nanoparticles, and multiwalled carbon nanotubes.

Authors:  Magdalena Popławska; Hanna Krawczyk
Journal:  Biomed Res Int       Date:  2013-09-02       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.